Literature DB >> 27593263

Risk factors for the severity and mortality of pneumococcal pneumonia: Importance of premorbid patients' performance status.

Takashi Ishiguro1, Naho Kagiyama2, Ryuji Uozumi3, Kyuto Odashima2, Kazuyoshi Kurashima2, Satoshi Morita3, Noboru Takayanagi2.   

Abstract

Comorbidity is known to be associated with the severity and mortality of pneumonia. The severity of each underlying disease varies, and performance status, which is known to be a prognostic factor of malignant diseases, reflects the overall patient condition as affected by his/her comorbidity and underlying diseases of various severity. We investigated whether premorbid patients' performance status is associated with the severity and mortality of pneumococcal pneumonia. This retrospective study assessed these factors in hospitalized patients suffering from pneumococcal pneumonia from 2002 to 2015. We included 424 patients aged 68.9 ± 14.1 years in the study, of which 68.9% were men. A multivariate analysis found that advanced age (≥65 years), diabetes mellitus, and poor performance status were independent factors associated with severity, whereas old pulmonary tuberculosis, poor performance status, pneumococcal bacteremia, and severe pneumonia were independent factors that were associated with non-survival. Poor performance status was associated with the severity and mortality of pneumococcal pneumonia.
Copyright © 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mortality; Performance status; Pneumococcal pneumonia; Prognostic factor; Severe; Streptococcus pneumoniae

Mesh:

Year:  2016        PMID: 27593263     DOI: 10.1016/j.jiac.2016.07.008

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  7 in total

1.  A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma.

Authors:  Shunsuke Tamura; Yukiyasu Okamura; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Katsuhisa Ohgi; Shigeyuki Murayama; Katsuhiko Uesaka
Journal:  Surg Today       Date:  2019-10-10       Impact factor: 2.549

2.  Declined Functional Status Prolonged Hospital Stay for Community-Acquired Pneumonia in Seniors.

Authors:  Hao Chen; Yu Hara; Nobuyuki Horita; Yusuke Saigusa; Yoshihiro Hirai; Takeshi Kaneko
Journal:  Clin Interv Aging       Date:  2020-08-27       Impact factor: 4.458

3.  Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities.

Authors:  Leyre Serrano Fernández; Luis Alberto Ruiz Iturriaga; Pedro Pablo España Yandiola; Raúl Méndez Ocaña; Silvia Pérez Fernández; Eva Tabernero Huget; Ane Uranga Echeverria; Paula Gonzalez Jimenez; Patricia García Hontoria; Antoni Torres Martí; Rosario Menendez Villanueva; Rafael Zalacain Jorge
Journal:  Int J Infect Dis       Date:  2021-11-18       Impact factor: 12.074

4.  Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia.

Authors:  Nancy Thabet; Yuichiro Shindo; Junya Okumura; Masahiro Sano; Toshihiro Sakakibara; Yasushi Murakami; Hironori Kobayashi; Hideo Saka; Masashi Kondo; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2022-05       Impact factor: 0.794

5.  Is rehabilitation effective in preventing decreased functional status after community-acquired pneumonia in elderly patients? Results from a multicentre, retrospective observational study.

Authors:  Hao Chen; Yu Hara; Nobuyuki Horita; Yusuke Saigusa; Yoshihiro Hirai; Takeshi Kaneko
Journal:  BMJ Open       Date:  2022-09-15       Impact factor: 3.006

6.  Clinical characteristics and prognostic factors of pneumonia in patients with and without rheumatoid arthritis.

Authors:  Aya Wakabayashi; Takashi Ishiguro; Yotaro Takaku; Yosuke Miyahara; Naho Kagiyama; Noboru Takayanagi
Journal:  PLoS One       Date:  2018-08-03       Impact factor: 3.240

7.  A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.

Authors:  Kenji Kawakami; Atsushi Nakamura; Akira Wakana; Temitope A Folaranmi; Tomoharu Iino
Journal:  Hum Vaccin Immunother       Date:  2019-12-04       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.